Anterogen.Co.,Ltd. announced that it expects to receive KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm
October 03, 2018
Share
Anterogen Co.,Ltd. (KOSDAQ:A065660) announced a private placement of 242,845 registered convertible preferred shares at a price of KRW 82,354 per share for gross proceeds of KRW 19,999,257,130 on October 4, 2018. The transaction will include participation from new investors NH Investment & Securities Co., Ltd., Investment Arm for 200,532 shares, KB Securities Co., Ltd., Investment Arm for 12,140 shares, and Mirae Asset Daewoo Co., Ltd., Investment Arm for 6,070 shares. The shares are issued at premium and have a face value of KRW 500 per share. The preferred shares are convertible into common shares of the company. The conversion period of the shares will be from November 1, 2019 to October 31, 2023. The securities issued are subject to a one year hold period. The transaction has been approved by the board of directors of the company. The payment date is October 31, 2018.
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
Anterogen.Co.,Ltd. announced that it expects to receive KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm